Use of TpCO2 (Transcutaneous CO2 Measurement) as PaCO2 Predictor During NIV in Case of Acute Hypercapnic Respiratory Failure (TpCO2-NIV)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2013 by University of Lausanne Hospitals.
Recruitment status was  Recruiting
Information provided by (Responsible Party):
Prof. Philippe Jolliet, University of Lausanne Hospitals Identifier:
First received: May 15, 2013
Last updated: May 23, 2013
Last verified: May 2013

In patients suffering from hypercapnic respiratory failure and treated by non invasive ventilation (NIV), the interest of using transcutaneous CO2 measurement to evaluate PaCO2 and PaCO2 variation over time is unknown and will be evaluated in this study. Measurements will be done during one-hour NIV treatments.

Hypercapnic Respiratory Failure

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Use of TpCO2 (Transcutaneous CO2 Measurement)as PaCO2 Predictor During Non Invasive Ventilation (NIV) in Case of Acute Hypercapnic Respiratory Failure

Resource links provided by NLM:

Further study details as provided by University of Lausanne Hospitals:

Primary Outcome Measures:
  • Comparison between TpCO2 (transcutaneous non invasive CO2 partial pressure measurement) and PaCO2 (obtained by blood gas analysis) values during NIV treatment. [ Time Frame: sixty minutes ] [ Designated as safety issue: No ]

Estimated Enrollment: 30
Study Start Date: February 2013
Estimated Study Completion Date: February 2014
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Intensive care unit patients equipped with an arterial line and requiring non invasive ventilation because of acute hypercapnic respiratory failure


Inclusion Criteria:

  • ICU patient equipped with an arterial line
  • NIV treatment prescribed by the clinician in charge
  • Hypercapnia defined by PaCO2> 42mmHg

Exclusion Criteria:

  • Severe hemodynamic instability
  • Severe psychiatric disorders
  • Denied consent
  • Age < 18 years
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01857635

Contact: Lise Piquilloud, Dr
Contact: Philippe Jolliet, Prof

Intensive care and burn unit, University hospital of Lausanne Recruiting
Lausanne, Switzerland, 1011
Contact: Lise Piquilloud, Dr   
Contact: Philippe Jolliet, Prof   
Principal Investigator: Philippe Jolliet, Professor         
Sub-Investigator: Lise Piquilloud, Dr         
Sub-Investigator: David Thévoz         
Sub-Investigator: Jean-Pierre Revelly, Dr         
Sponsors and Collaborators
University of Lausanne Hospitals
Principal Investigator: Philippe Jolliet, Prof University of Lausanne Hospitals
  More Information

No publications provided

Responsible Party: Prof. Philippe Jolliet, Principal investigator, University of Lausanne Hospitals Identifier: NCT01857635     History of Changes
Other Study ID Numbers: TpCO2-NIV
Study First Received: May 15, 2013
Last Updated: May 23, 2013
Health Authority: Switzerland: Laws and standards

Keywords provided by University of Lausanne Hospitals:
Acute respiratory failure
Non invasive ventilation
Transcutaneous CO2 measurement

Additional relevant MeSH terms:
Respiratory Insufficiency
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms
Signs and Symptoms, Respiratory processed this record on May 21, 2015